Intravenous zoledronic acid in postmenopausal women with low bone mineral density

I Reid, J. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J.p. Devogelaer, J.-M. Kaufman, P. Jaeger, J.j Body, M. Brandi, J. Broell, R. Di Micco, A. Genazzani, D. Felsenberg, J. Happ, M. Hooper, J. Ittner, G. LebH. Mallmin, T. Murray, S. Ortolani, A; Rubinacci, M. Saaf, G. Samsioe, Leon Verbruggen, J.-P. Meunier

Research output: Contribution to journalArticlepeer-review

749 Citations (Scopus)



Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored.


We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at three-month intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density was the primary end point.


There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P

Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic acid might be an effective treatment for postmenopausal osteoporosis.
Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalNew England Journal of Medicine
Issue number9
Publication statusPublished - 2002


  • postmenopausal
  • low bone mineral density
  • Intravenous zoledronic acid
  • osteoporosis


Dive into the research topics of 'Intravenous zoledronic acid in postmenopausal women with low bone mineral density'. Together they form a unique fingerprint.

Cite this